In this work, CLCA2 silencing also resulted in cells’ increased viability after TMZ treatment (Figure 2B), indicating this is also an exciting target for clinical therapy for glioblastoma patients, when used in combination with TMZ. This evidence concerns the gene CLCA2 and glioblastoma.